Dr. Andrew M. Dahlem is the Chairman of the Board at Syra Health. He has had a distinguished career in the fields of medicine and research. Since November 2018, Dr. Dahlem has served as a Senior Research Professor of Medicine at the Indiana University School of Medicine, where he also held the role of Chief of the Division of Clinical Pharmacology until May 2022.
In addition to his academic role, Dr. Dahlem is the co-founder and an advisor to Gate Neurosciences, a biotechnology company that focuses on developing new therapies for treatment-resistant depression, since April 2019. He is also the President of Dr. Dahlem Consulting LLC, where he advises on the discovery and development of novel therapeutics for academia, biotech, and the pharmaceutical industry, a position he has held since May 2018.
Dr. Dahlem’s career includes significant experience in the biopharmaceutical industry. He worked at Lilly for 30 years, where he served as Vice President of Research Operations and Chief Operating Officer of Lilly Research Laboratories and Lilly Research Laboratories Europe. He retired from Lilly in December 2017.
Deepika Vuppalanchi, PhD, is the CEO, and Co-Founder of Syra Health. A senior leader with over 20 years of experience in healthcare and medical research, she is a recognized thought leader in medical sciences. Dr. Vuppalanchi has authored numerous peer-reviewed publications in neuroscience and molecular biology. In her previous roles, she led strategy and tactical execution of medical marketing and education for billion-dollar drugs across therapeutic areas, working closely with top pharmaceutical companies. She has held senior leadership positions at Precision For Value, Symbiotix, and DWA Healthcare Communications.
Priya Prasad is Chief Operating Officer & Chief Financial Officer of Syra Health. Priya has nearly 20 years of experience in finance and operations. She has served as president of STLogics for nearly 20 years and is a board member for RADcube and Skill Demand Energy. She holds an MBA from the University of Massachusetts, Boston, and a Master of Science degree from Bangalore University.
Ms. Rogers has served as Chief Financial Officer of Johns Hopkins All Children’s Hospital, since March 2022. Previously, Ms. Rogers served as Chief Financial Officer and Chief Strategy Officer of Eskenazi Health. She was with Eskenazi Health from 2016-2022 leading growth and improvement initiatives. She spent over a decade at Indiana University Health in leadership roles. Prior to healthcare, Ms. Rogers was in manufacturing at Cummins, Inc. focused on global and administrative process improvement.
Dr. Reddy has served as an Advisor and Director of VIPRA, LLC, a consulting company, since August 2017. From 2007 to 2017, Dr. Reddy served as a Senior Researcher Advisor/Executive Director of Lilly Research Laboratories, where he led nonclinical safety and regulatory assessments of several cross-functional programs at different stages of development.
Dr. Paranjape is Chief Operating Officer and Vice President of Enterprise Imaging for Optum. Previously, Dr. Paranjape served in various leadership roles at Roche Diagnostics, including as Vice President of Information Solutions, Vice President of Commercial Business Operations, and Vice President of Business Intelligence and Analytics.
Dr. Avutu has over 27 years of corporate leadership experience in strategy & innovation. Since joining Dow AgroSciences, he has held multiple leadership roles, managing project budgets, pipeline financial assessments and due diligence for M&As. He currently serves as the Scientific Strategic and Emerging Business Intelligence Leader at Corteva Agriscience. Before transitioning to industry, Dr. Avutu was an Asst. Professor & Director of Genomics at Texas A&M University. He has authored over 50 publications and holds over 30 patents.